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ORIGINAL ARTICLE VIROLOGYSymptomatic cytomegalovirus gastrointestinal infection with positive
quantitative real-time PCR ﬁndings in apparently immunocompetent
patients: a case seriesS. Bernard1, R. Germi2,3, J. Lupo2,3, M.-H. Laverrière4, V. Masse5, P. Morand2,3 and G. Gavazzi6
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Hospital, Sherbrooke, Quebec, Canada and 6) University Clinic of Geriatric Medicine, Grenoble University Hospital, Grenoble, FranceAbstractCytomegalovirus (CMV) gastrointestinal disease rarely occurs in immunocompetent patients, and is mainly diagnosed on the basis of
histopathological ﬁndings. Real-time PCR for CMV DNA quantiﬁcation is considered to be a useful diagnostic tool, but its place in the
diagnostic strategy is not clearly deﬁned. The goal of the study was to describe the clinical and paraclinical features of apparently
immunocompetent patients with CMV gastrointestinal disease diagnosed according to quantitative PCR results. In this retrospective study
conducted in a 1500-bed tertiary-care centre, we reviewed the case records of apparently immunocompetent patients with positive
ﬁndings of CMV DNA in gastrointestinal biopsies with compatible symptoms and endoscopic ﬁndings. A total of 13 patients were
included between January 2007 and December 2010. The median age was 81 years, and 54% of patients had underlying immune-
modulating conditions. Diarrhoea, haematochezia and dysphagia were the main reported symptoms, and ulcers were the main endoscopic
ﬁndings. The mean value of CMV DNA load in gastrointestinal biopsies was 3845 copies/μg total DNA (range, 15–15 500 copies/μg total
DNA). The highest values were found in two patients who were diagnosed with adenocarcinoma in the subsequent course of CMV
infection. Clinical features were similar to those in previous series in which diagnosis was based on histopathological analysis. Elderly
people are more commonly affected, and a link with immune senescence is possible. Quantiﬁcation of CMV DNA seems to be a useful
tool for diagnosis when combined with clinical and endoscopic ﬁndings, but further studies are necessary to interpret quantitative values.
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E-mail: Sbernard@chu-grenoble.frIntroductionCytomegalovirus (CMV) disease rarely occurs in people with
normal immune function, but is more commonly diagnosed in
immunosuppressed patients (especially those with humanClinical Microbiology and Infection © 2015 European Society of Cimmunodeﬁciency virus (HIV), transplant recipients, those with
malignant diseases, those with inﬂammatory bowel diseases
(IBDs) receiving treatment, and those undergoing chemo-
therapy or steroid therapy); gastrointestinal (GI) involvement is
a classic and frequent manifestation of the disease in those
patients [1,2]. Reports of GI CMV disease in immunocompe-
tent patients have been limited to several case reports and a
few case series [3–5]. Active infection in the GI tract usually
results either from endogenous reactivation or from exoge-
nous re-infection with another virus strain [6,7]. The most
common sites of GI involvement are the colon and the upper
GI tract [8,9]. Diarrhoea, weight loss, abdominal pain,Clin Microbiol Infect 2015; 21: 1121.e1–1121.e7
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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spectrum of endoscopic lesions ranges from patchy erythema
to deep ulcers [11]. Most reports are based on histopatho-
logical analysis demonstrating active disease, which is consid-
ered to be the reference standard for diagnosis. Diagnosis of
invasive disease is not straightforward, as the presence of CMV
in a diseased tissue does not necessarily imply a causal rela-
tionship [12]. Quantitative real-time PCR (rtPCR) has recently
been used in a few studies to diagnose CMV GI disease,
particularly in IBD patients [13,14]. However, because of its
high sensitivity, there is a need to distinguish between latent
infection and active disease. The results have to be combined
with clinical symptoms from the upper or lower gastrointes-
tinal tract, endoscopic ﬁndings, or demonstration of CMV
infection in a GI tract biopsy specimen with other techniques
(culture, histopathological testing, immunohistochemical anal-
ysis, or in-situ hybridization) [11]. Nonetheless, only a few
published studies have combined quantitative rtPCR with
clinically relevant symptoms to diagnose CMV GI disease
[15–17].
The aim of our study was to describe the clinical features of
apparently immunocompetent patients with a diagnosis of CMV
GI disease based on quantitative rtPCR on GI biopsy specimens,
clinical symptoms, and endoscopic ﬁndings.Materials and methodsWe performed a retrospective descriptive case series of
symptomatic CMV GI infection in apparently immunocompe-
tent adults (aged 18 years) in a 1500-bed tertiary-care
centre during the period January 2007 to December 2010.
Cases were ﬁrst identiﬁed from the virology laboratory
database, on the basis of positive results of quantitative rtPCR
performed on GI tissue biopsy samples. All patients with
CMV-related clinical symptoms, macroscopic endoscopic
ﬁndings, absence of other digestive pathogens, and no
apparent immunodeﬁciency at the time of diagnosis, such as
congenital immunodeﬁciency, prior cancer therapy, haemato-
logical malignancy, organ transplantation, AIDS, prolonged
steroid therapy, and receiving treatment for IBD, were
included in the case series.
Patients’ demographic characteristics, medical history,
symptoms at the onset of the disease, serological status, anti-
viral treatment and evolution were ascertained through a
manual chart review. Immune-modulating conditions such as
diabetes mellitus, hepatic failure, chronic renal failure, malnu-
trition (with related severe hypoalbuminaemia), non-
haematological malignancies and autoimmune diseases were
also recorded.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectQuantitative rtPCR for CMV DNA
Biopsy samples were incubated with 180 μL of tissue lysis
buffer (Qiagen, Coutaboeuf, France) and 20 μL of protein ki-
nase (concentration 600 mAU/mL; Novagen, Darmstadt, Ger-
many) for 20 min at 56°C, and lysed with the MagnaLyser
instrument (Roche Applied Science, Meylan, France). Total
DNA from lysed biopsies was extracted with the QIAamp
DNA mini kit (Qiagen) according to the manufacturer’s rec-
ommendations. The extraction efﬁciency was veriﬁed by adding
an internal control to the sample, and an external negative
control was used to detect possible contamination. The num-
ber of CMV copies was then determined from 1 μg of total
DNA (measured on a spectrophotometer at 260/280 nm) by
the use of rtPCR. From 2007 to 2009, CMV DNA quantiﬁca-
tion was carried out with primers and a probe targeting the
UL83 region [18], and the LightCycler-DNAMaster-
Hybridization-Probes-Kit (Roche Applied Science). In 2010,
CMV viral loads were measured with the CMV R-gene quan-
tiﬁcation kit (Argene, Verniolle, France).
To compare CMV rtPCR with histological analysis, biopsy
samples were examined for enlarged nuclei and viral inclusions,
and immunohistochemical staining for CMV (monoclonal
mouse antibody, clone CCH2; DakoCytomation, Hamburg,
Germany) was performed. CMV histopathological determina-
tion was conﬁrmed if either of these methods yielded a positive
result.
Analysis
We described patient characteristics by using frequency, me-
dian, mean, range and summary data.ResultsPatient characteristics, clinical manifestations, and
endoscopic and radiological features
Between January 2007 and December 2010, 17% (185/1061) of
quantitative rtPCRs performed on GI tract biopsy samples gave
positive ﬁndings, mostly in immunosuppressed patients (90%,
166/185). We ﬁnally found 15 biopsy samples that were posi-
tive for CMV by quantitative rtPCR in 13 apparently immuno-
competent patients who had clinically relevant symptoms
related to CMV (Fig. 1). Patient characteristics are summarized
in Table 1. The median age was 81 years (mean, 75 years; range,
54–88 years), and ﬁve (38%) were men. Negative HIV-1 and
HIV-2 serological results were retrospectively available for only
eight patients (61%). However, of the patients without available
HIV serological results, none had lymphopenia (<1500 lym-
phocytes/mm3) or was likely to have AIDS (risk factors). At the
time of diagnosis, seven patients (54%) had known immune-ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1121.e1–1121.e7
1061 CMV rtPCRs on   
185 positive results
166 positive rtPCRs for 110  
immunocompromised patients
19 positive rtPCRs for 17
immunocompetent patients
IBD*: 50                 
Haematological malignancies: 17
Transplant organ: 19                
Solid neoplasic: 4                             
AIDS : 5                                             
Others : 15
15 positive rtPCRs for 13
immunocompetent patients
4 rtPCRs for 4 patients with other  
causative pathogens or non-
compatible macroscopic 
endoscopic findings
gastrointestinal biopsy 
samples
FIG. 1. Flow chart of cytomegalovirus
(CMV) quantitative real-time PCR
(rtPCR) performed on gastrointestinal
biopsy samples between January 2007 and
December 2010. IBD, inﬂammatory
bowel diseases. *Receiving treatment.
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severe hypoalbuminaemia (25 g/L). The median time of the
onset of symptoms before hospitalization was 8 days (range,
1–30 days). Leukocytosis was noted in three cases (23%); no
lymphocytosis was observed, but two cases of lymphopenia
were found for HIV-negative patients. The median C-reactive
protein level was 59 mg/L (range, 4–169 mg/L) at the time of
diagnosis. Eight patients (61%) had a computed tomography
scan, which showed non-speciﬁc wall thickening in six of eight
cases (75%). Case 8 had a normal computed tomography scan
at the site of CMV disease.
Diagnostic strategies
CMV serological status was available for ten patients, all of
whom had a reactivation proﬁle (signiﬁcant increase in CMV-
speciﬁc IgG antibody titre with or without the presence of
speciﬁc IgM antibodies). The mean CMV DNA load found in GIClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infebiopsy samples was 3845 copies/μg DNA (median, 1150 copies/
μg DNA; range, 15–15 500 copies/μg DNA). Histopathological
analysis was positive for only one patient (case 5) according to
the case deﬁnition. The CMV DNA load in the biopsy sample of
this patient was 2860 copies/μg DNA. The CMV DNA load in
blood was assessed in only four patients, and was positive in
one case (case 3, 3500 copies/μg DNA).
Length of stay, antiviral therapy, and follow-up
The mean length hospital stay was 23 days (range, 2–47 days).
Only one patient stayed for <5 days (case 6), as he was
admitted solely for endoscopy. Six patients received antiviral
therapy: generally intravenous ganciclovir followed by oral
valganciclovir for a total of 3 weeks of treatment (4/6, 67%).
Two patients received valganciclovir alone for 17 days and 21
days (cases 5 and 11, respectively). In treated patients, no
speciﬁc complications (e.g. myelosuppression or acute renalctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1121.e1–1121.e7
TABLE 1. Characteristics of 13 immunocompetent cases of cytomegalovirus (CMV) gastrointestinal disease
Patient
Age
(years)/
sex
IM conditions/number
of other comorbidities
Clinical
manifestations
Endoscopy ﬁndings at
site of positive biopsy Tomodensitometry
CMV
serological
status
CMV DNA load
(copies/μg DNA) Histology
Therapy after diagnosis
(length in days)
Length of
hospital stay
(days)
Other active concurrent
disease
1 69/M Type 2 diabetes/1 Fever and
diarrhoea
Sigmoid ulcer — Reactivation
proﬁle
1150 Negative Supportive treatment
(probabilist
antibiotherapy)
5 No
2 83/F Diabetes mellitus, chronic
renal failure/2
Haematemesis Oesophageal ulcer with
conﬂuent erosions
— Not
determined
2675 Negative Supportive treatment 27 No
3a 71/M No IM conditions/8 Diarrhoea Rectal petechiae and
whitish plaques
Rectal and colic wall
thickening
Reactivation
proﬁle
11 750 Negative Intravenous ganciclovir (3),
then oral valganciclovir
(24)
18 No
4 88/F Chronic renal failure,
malnutrition/3
Haematochezia Rectal ulcer (3 cm) Inﬁltration of
presacral region
Reactivation
proﬁle
918 Negative Intravenous ganciclovir (5),
then oral valganciclovir (7)
42 No
5 80/F No IM conditions/4 Bloody
diarrhoea
Deep sigmoid ulcers — Reactivation
proﬁle
2860 Positive Oral valganciclovir (17) 33 Refractory ulcerative colitis
needed total colectomy
6 83/M No IM conditions/5 Dysphagia Oesophageal ulcer with
stenosis
— Not
determined
1074 Negative Supportive treatment 2 No
7 84/F Type 1 diabetes,
malnutrition/4
Fever and
diarrhoea
Wide sigmoid ulcers Sigmoidorectal wall
thickening
Reactivation
proﬁle
11 800 Negative Intravenous ganciclovir (3),
then oral valganciclovir
(21)
47 Breast adenocarcinoma
8 83/M No IM conditions/6 Dysphagia,
haematemesis
Ulcerative oesophagitis Normal sus-
diaphragmatic
Reactivation
proﬁle
15 500 Negative Intravenous ganciclovir (5),
then oral valganciclovir
(16)
19 Adenocarcinoma of sigmoid
with peritoneal carcinosis
9 54/M Chronic alcoholism/3 Dysphagia,
haematemesis
Necrotic oesophagitis Oesophageal wall
thickening (13 mm)
Reactivation
proﬁle
173 Negative Supportive treatment 26 No
10a 65/F No IM conditions/0 Haematochezia Multiple rectal ulcers Sigmoid wall
thickening (9 mm)
Not
determined
15 Negative Supportive treatment 41 No
11 81/F Malnutrition/4 Fever and
diarrhoea
Duodenal erosion Dudodenal and colic
wall thickening
Reactivation
proﬁle
64 Negative Oral valganciclovir (21) 14 No
12 84/M No IM conditions/3 Dysphagia Severe oesophagitis — Reactivation
proﬁle
84 Negative Supportive treatment 15 Occlusive syndrome,
resolved with medical
treatment
13 56/F Malnutrition/3 Fever and
chronic
diarrhoea
Deep sigmoid ulcers Ileocolic wall
thickening
Reactivation
proﬁle
1920 Negative Supportive treatment 10 Crohn’s disease
F, female; IM, immune-modulating; M, male.
aSymptoms appeared after the onset of hospitalization.
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CMI Bernard et al. Symptomatic cytomegalovirus gastrointestinal infection 1121.e5failure) warranted treatment cessation. No CMV-related deaths
were observed during the hospitalization period. Three cases
receiving antiviral treatment had biopsy controls performed
with quantitative rtPCR for CMV at 1 month following the ﬁrst
sample. Case 7 showed complete negativation of viral count,
and a dramatic decrease was observed for case 8 (15 500 to
21 copies/μg DNA) and case 5 (2860 to 54 copies/μg DNA).
Concurrent active immune-modulating diseases
diagnosed after CMV GI disease
In four cases (5, 7, 8, and 13), the diagnosis of CMV disease was
followed by the diagnosis of other concurrent morbidities. Two
patients had both persistent symptoms and endoscopic and
histological lesions compatible with IBD (one Crohn’s disease
and one ulcerative rectocolitis). Case 7 was diagnosed with
breast adenocarcinoma 2 months after sigmoid CMV infection.
No speciﬁc therapy was undertaken, owing to her many asso-
ciated comorbidities. Case 8 underwent surgical treatment for
colic adenocarcinoma with peritoneal carcinomatosis that was
diagnosed during his hospital stay. These four patients had a
mean CMV DNA load higher (1989 vs. 8020 copies/μg DNA)
than that of other cases. Moreover, the two cases (7 and 8)
with adenocarcinoma had the highest CMV DNA loads (11 800
and 15 500 copies/μg DNA, respectively) on GI biopsy.DiscussionThis study is the ﬁrst published case series of CMV GI disease in
apparently immunocompetent patients with a diagnosis based
on quantitative rtPCR CMV results. Overall, our results
conﬁrm the ﬁndings of previous case series that included two
or more apparently immunocompetent patients with the diag-
nosis based on histology [9,19]. Table 2 compares the results of
three previous case series and three reviews with those of ourTABLE 2. Previously published case series on cytomegalovirus (CM
Variable
Case series
Ng et al. (1999)
[9] (n [ 10)
Maionara et al.
(2003) [19]
(n [ 11)
Seo et
(2012)
(n [ 1
Age in years (mean) 71 72 66
Female sex (%) 90 22 50
Immune-modulating
conditions (%)
NA NA 58
Upper digestive tract involvement (%) 0 45 0
Diagnosis method Histology Histology Histolog
Primary infection (%) 0 NA NA
Spontaneous remission (%) 70 NA NA
Other immune-modulating diseases
diagnosed after CMV
0 4 neoplasia NA
IBD, inﬂammatory bowel disease; NA, not available; rtPCR, real-time PCR.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecurrent study [3–5,7,9,19]. Elderly people (mean age, 75 years)
are generally affected by the disease, and the majority of cases
had underlying immune-modulating diseases (54%). Two cases
of non-haematological malignancy were found in the subse-
quent course of the viral infection. These cases had the highest
CMV loads of the case series.
Several factors could explain why elderly people are more
frequently affected. Ageing is associated with a decline in
immunological function, a concept termed ‘immune senes-
cence’. This refers to impairment in immunity as a result of age-
associated changes in function in a variety of cells. It is a phe-
nomenon of decreased function, involving changes to both
innate and adaptive immunity and an imbalance between the
two arms [20]. Reports have shown that it probably increases
the morbidity and mortality associated with infection [21]. CMV
has been implicated in immune senescence mechanisms: CMV
infection is likely to be not strictly latent, and asymptomatic
reactivation leads to continuous production of viral proteins
and, as a consequence, to chronic antigenic stimulation, accel-
erating the exhaustion of the naïve T-cell pool, especially in the
absence of adequate T-cell renewal from the thymus [20,22]. A
poor T-cell response is particularly implicated in viral reac-
tivation of herpesviruses [21]. In our case series, CMV may be a
cause of immune senescence or a consequence of this senes-
cence as a disease manifestation precipitated by other under-
lying immune-modulating conditions such as cancer. Clinical
manifestations could reﬂect the imbalance in the homeostatic
control of persistent viral infections caused by CMV. Comor-
bidities also have an impact on infectious diseases encountered
in elderly patients, particularly immune-modulating conditions
such as diabetes and malnutrition [23]. Previous studies showed
that immune-modulating conditions were frequently associated
with CMV GI disease (36–58%) [3,5,7]. In our study, only ﬁve
cases were free of immune-modulating conditions, and only one
case (case 10) was free of any comorbidity. Also, theV) gastrointestinal disease in immunocompetent patients
Reviews
al.
[5]
2)
Current study
(n [ 13)
Klauber et al.
(1998) [3]
(n [ 15)
Galiatsos
et al. (2005)
[7] (n [ 44)
Karigane
et al. (2014)
[4] (n [ 33)
75 57 61 68
54 33 16 51
54 40 36 NA
38 0 0 0
y Quantitative rtPCR Histology Histology Histology
0 47 29 NA
54 NA 32 24.2
2 IBD and 2 neoplasia 3 IBD NA NA
ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1121.e1–1121.e7
1121.e6 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIunderstanding of immune senescence in elderly people should
lead us to reconsider the presumed immunocompetence of this
population, particularly regarding CMV infection. We observed
that the mean age was lower in reviews (Table 2), because cases
of primary infection were included [3,7]. In our and other
published case series on CMV GI disease for which CMV
serological status was available, no cases of primary infection
were found, which is consistent with the high level of sero-
prevalence (90%) found in persons aged >80 years [9,22,24].
Although histology is considered to be the reference stan-
dard for the diagnosis of CMV GI disease, it suffers from many
limitations, notably a lack of sensitivity and a dependence on
sample quality and the examiner’s experience [25]. The auto-
mated molecular assays were introduced a few years ago, and
seem to yield reliable results [10]. Recent studies have reported
that CMV DNA quantiﬁcation in GI biopsy samples could be
useful for diagnosing CMV GI disease, but a well-deﬁned cut-off
still needs to be validated to improve the speciﬁcity of this test
[18,26]. One study aimed to interpret CMV DNA quantiﬁcation
in 163 lower-intestine biopsy samples from immunocompro-
mised patients. The results of this study indicated that histo-
pathology alone was not sensitive enough to be a suitable
reference standard [13]. Therefore, Ganzenmueller et al.
established a cut-off for intestinal CMV DNA load that was
predictive for CMV intestinal disease by using histopathological
(cut-off: 23 240 copies/μg DNA) or clinical (cut-off: 1660
copies/μg DNA) criteria as a reference standard to attribute
intestinal illness to CMV. Application of these cut-offs to our
results indicates that six patients ﬁt the clinical deﬁnition,
whereas none of the patients corresponds to the histological
diagnosis. These cut-off values were deﬁned for patients with
underlying immunodeﬁciency conditions, and we can hypothe-
size that there is a higher level of CMV replication in these
patients, as was previously described for CMV viral load in
peripheral blood leukocytes during CMV primary infection [27].
Even if histopathological testing cannot be replaced, quantiﬁ-
cation of CMV DNA in intestinal biopsy samples by rtPCR is a
useful diagnostic tool with high sensitivity, and this method is
objective, fast, and highly standardized. In cases of negative
histopathological results, CMV-associated disease should be
diagnosed on clinical grounds (symptoms, endoscopic lesions,
and absence of other pathogens) in combination with detection
of virus by quantitative rtPCR [13]. The main challenge with
quantitative rtPCR CMV on GI biopsy samples remains the
interpretation of quantitative positive results. In our study, we
observed low viral loads, as in patients 10, 11, and 12. We
interpret these low viral loads as positive results for CMV,
because of the association of clinical and endoscopic signs of
this possible infection and the absence of other pathogens, but
the imputability could be more questionable than in other casesClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectwith higher viral loads in tissue biopsy samples, because of the
high sensitivity of nucleic acid detection. Further studies are
needed to evaluate the value of GI CMV DNA load in different
populations with different degrees of clinical severity and
immunodeﬁciency.
As in previous studies, the CMV DNA load in blood was
negative for three of four patients, suggesting localized repli-
cation in the digestive tract only [27,28].
The efﬁcacy of treatment could not be assessed, because of
our small number of cases, limited follow-up, and the fact that
patients who received speciﬁc therapy probably had more se-
vere disease. No previous study (Table 2) evaluated the efﬁcacy
of treatment; we noted that spontaneous remission varied
between 24% and 70%. Mortality is difﬁcult to assess, because
of several potential biases, such as comorbidities, malnutrition,
and low functional status, particularly in elderly patients.
Two cases of CMV GI disease were associated with IBD
diagnosis during the same period of hospitalization. CMV has
been reported to assume a triggering role in the onset or
worsening of IBD exacerbations, and to have a role in steroid
refractoriness [14]. No clear guidelines have been proposed for
therapeutic management in these situations. It is now believed
that one-third of all new cases of Crohn’s disease occur in the
elderly population. Misdiagnosis at the initial presentation is
more common in the elderly (60% as compared with 15% of the
younger population). The delay in diagnosis is also longer (up to
6 years in elderly IBD patients, as compared with 2 years in
younger IBD patients) [29].
Two cases of solid malignancy have followed the diagnosis of
CMV GI disease. A possible link between viral infection and GI
cancer has been studied, but the results are controversial. A
recent study on 56 colorectal biopsy samples of different can-
cer phenotypes suggested no evidence of a direct association
between CMV and colorectal cancer [30]. In our series, CMV
infections reached the digestive tract, but cancer was diagnosed
at a distant site. The impact of cancer on the immune system
could have led to CMV reactivation. We noted that these two
cases had the highest CMV DNA loads in GI biopsy samples.
No conclusions can be drawn, but further evaluation should be
undertaken to determine whether patients with high CMV
DNA load warrant extensive cancer work-up.
The limitations of our study are mainly related to its retro-
spective nature. The small number of cases, missing data and
short follow-up limit the conclusions that can be drawn.
Our study conﬁrms the few clinical data for this rare disease,
which mainly affects elderly patients. Because there is a speciﬁc
link between CMV infection and ageing, it would be of interest
to study more extensively the symptoms and outcomes of CMV
infection in elderly patients. Quantitative rtPCR for CMV DNA
seems to be an accurate tool for diagnosis (if associated withious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1121.e1–1121.e7
CMI Bernard et al. Symptomatic cytomegalovirus gastrointestinal infection 1121.e7compatible clinical and endoscopic lesions, to avoid over-
diagnosis due to the possible detection of latent CMV), with
higher sensitivity than histology, and may help to improve the
diagnosis of CMV infection.Author contributionsS. Bernard: study concept and design, acquisition of subjects and
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